Reviewer's report
Title:Efficacy of bevacizumab and chemotherapy in the first-line treatment of
metastatic colorectal cancer: broadening KRAS-focused clinical view
Version:2Date:26 December 2014
Reviewer: Yi Ba
Reviewer's report:
Discretionary Revisions
1. Previous evidence has shown that there is no association between KRAS
status and efficacy of bevacizumab in mCRC, but most of them were based on
subgroup analysis of phase III trials. The present manuscript is a large-scale
retrospective study that evaluated the prognostic and predictive value of KRAS
status in mCRC patients treated with bevacizumab plus chemotherapy which is
widely used in clinical practice.
2. In this paper, the investigators defined KRAS mutation only in matations on
exon 2, more evidence suggested RAS status including KRAS (both exon 2 and
non-exon 2) and NRAS may have stronger predictive and prognostic value in
treatment of mCRC using anti-EGFR therapy, but its value in treatment using
anti-VEGF therapy is still unknown.The results would be more valuable if RAS
status being used in the analysis.
3. The subsequent treatment after first-line therapy would have significant
influence on OS. The manuscript gave information of subsequent anti-EGFR
therapy but failed to give information on second-line or third-line intensity of
chemotherapy in both groups.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Efficacy of bevacizumab and chemotherapy in the first-line treatment of
metastatic colorectal cancer: broadening KRAS-focused clinical view
Version:2Date:26 December 2014
Reviewer: Yi Ba
Reviewer's report:
Discretionary Revisions
1. Previous evidence has shown that there is no association between KRAS
status and efficacy of bevacizumab in mCRC, but most of them were based on
subgroup analysis of phase III trials. The present manuscript is a large-scale
retrospective study that evaluated the prognostic and predictive value of KRAS
status in mCRC patients treated with bevacizumab plus chemotherapy which is
widely used in clinical practice.
2. In this paper, the investigators defined KRAS mutation only in matations on
exon 2, more evidence suggested RAS status including KRAS (both exon 2 and
non-exon 2) and NRAS may have stronger predictive and prognostic value in
treatment of mCRC using anti-EGFR therapy, but its value in treatment using
anti-VEGF therapy is still unknown.The results would be more valuable if RAS
status being used in the analysis.
3. The subsequent treatment after first-line therapy would have significant
influence on OS. The manuscript gave information of subsequent anti-EGFR
therapy but failed to give information on second-line or third-line intensity of
chemotherapy in both groups.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Efficacy of bevacizumab and chemotherapy in the first-line treatment of
metastatic colorectal cancer: broadening KRAS-focused clinical view
Version:2Date:26 December 2014
Reviewer: Yi Ba
Reviewer's report:
Discretionary Revisions
1. Previous evidence has shown that there is no association between KRAS
status and efficacy of bevacizumab in mCRC, but most of them were based on
subgroup analysis of phase III trials. The present manuscript is a large-scale
retrospective study that evaluated the prognostic and predictive value of KRAS
status in mCRC patients treated with bevacizumab plus chemotherapy which is
widely used in clinical practice.
2. In this paper, the investigators defined KRAS mutation only in matations on
exon 2, more evidence suggested RAS status including KRAS (both exon 2 and
non-exon 2) and NRAS may have stronger predictive and prognostic value in
treatment of mCRC using anti-EGFR therapy, but its value in treatment using
anti-VEGF therapy is still unknown.The results would be more valuable if RAS
status being used in the analysis.
3. The subsequent treatment after first-line therapy would have significant
influence on OS. The manuscript gave information of subsequent anti-EGFR
therapy but failed to give information on second-line or third-line intensity of
chemotherapy in both groups.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
assistant